CEBIO is a green biotech company focusing on optimization of complex bioactive compounds (CBCs) for the life science and pharmaceutical industries. CBCs are efficient and potent medical building blocks, with a limited distribution and currently regarded as an unreliable and very costly product source. The technology platform CEBIO has under development is based on plants as ‘bioreactors’ for production of CBCs and holds promises for mass-production of CBCs – in quantities of 1-2 grams for research and larger quantities for products. Don’t hesitate to contact us for more information.

DelSiTech is an innovative Finnish drug delivery technology company that helps its customers to turn their active agents into novel and commercially viable therapeutic drug products. DelSiTech offers one-stop shop opportunity in drug delivery up to early clinical proof of concept. The Company’s proprietary drug delivery technology is based on biodegradable silica (SiO2) matrix into which the active ingredient is embedded. The matrix can be designed to biodegrade at the required rate to assure a tightly controlled release of the active substance, providing a better therapeutic effect in situ and causing lower systemic and local adverse effects than alternative delivery systems. DelSiTech also develops its own supergeneric drug products to address significant unmet medical and commercial needs. The lead product, 1308 is a long-acting subcutaneous depot injection that offers for the first time a patient-friendly slow release treatment option to chronic hepatitis B infection.

IBA GmbH is dedicated to high quality tools for life science research. We provide solutions for the entire production chain of recombinant proteins, from oligo synthesis, cloning, transfection, protein expression and purification, to detection, immobilization and assay. We also deliver new tools for immunology research with a growing line of tag-based reagents for cell isolation. We support our customers in the life sciences industry and academia from early discovery to commercialization. The know-how and innovative approach qualifies IBA as the ideal partner for the pharmaceutical and biotech industry.

InnoCore Pharmaceuticals is specialized in the development of long acting and minimally invasive injectable drug delivery products for the treatment of chronic diseases. At InnoCore, we serve the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. Our approach centres around our proprietary SynBiosys family of bioresorbable polymers. The SynBiosys platform allows the development of numerous different configurations resulting in the most versatile polymeric drug delivery systems today.

IVEX Lab helps investigators in their efforts to find safer and more effective treatments for major diseases, including cancer. Focusing to preclinical drug efficacy studies, our team can develop novel tools that meet your experimental needs, ranging from molecular cloning and stable expression to in vivo xenograft studies. IVEX Lab is CRO with highly experienced personnel as well as relevant technical infrastructure. We have implemented live animal imaging methodology that enables to perform experiments with high sensitivity, accuracy and speed, at the same time reducing animal numbers.

Lanthio Pharma is focused on discovering and developing lantipeptide drugs for serious diseases. We are working on lanthipeptides as new treatment for fibrosis, stroke, heart failure and multiple sclerosis. To discover and produce drug candidates, we apply our proprietary LanthioPep technology. This technology uses modified Lactococcus bacteria to make constrained peptides, called lanthipeptides. Our lanthipeptides are more disease target selective and more stable in plasma compared to linear wild-type peptides, making them more suitable as drug candidates.

The Ofichem Group manufactures, develops and distributes active pharmaceutical ingredients (APIs) for both the veterinary and human market. These active compounds are distributed worldwide to pharmaceutical producers. The production of APIs is in accordance with the guidelines of Good Manufacturing Practices (GMP). The Ofichem Group also has his own laboratory which doesn’t only analyse the produced APIs, but also analyses APIs for external clients.

Oslo Cancer Cluster is a non-profit member organization dedicated to accelerate the development of new cancer diagnostics and medicines through: Local collaboration and international partnerships; Stimulation and support of new innovations and start-up activities; strengthening of our member’s ability to attract capital; Improved clinical trial efficiency for our members; Increase of governmental focus and improved public policies for the cancer community, fostering and attracting the next generation of top talents to cancer R&D and entrepreneurship. In June 2007, the cluster became a Norwegian Centre of Expertise (NCE). Oslo Cancer Cluster has more than 70 members from Northern Europe, representing the entire oncology value chain from bench to bedside.

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development. We provide quality services to pharmaceutical and biotechnology clients Worldwide. QPS is well known as a leading CRO for CNS drug development. The availability of the most predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes turn QPS into the first choice for most research needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of AD, PD, HD and other neurodegenerative diseases.

RIEMSER Pharma GmbH, headquartered in Greifswald, Germany, is a midsize pharmaceutical company specialized in marketing and sophisticated life cycle management of specialty drugs for treatment of highly complex and niche disease areas. RIEMSER targets European markets but its products are distributed worldwide by a wide-ranging partner network. Our success and our ability to respond dynamically to new challenges are based on the expertise, experience and commitment of our employees. As Specialty Pharma Company, we specialise in medicinal products for the management of malignant diseases (oncology), infectious diseases (anti-infectives), skin conditions (dermatology)and dental products. Other important segments of our range of products include analgesics, cardiovascular products and OTC medicines.

Santara Valley is a biotechnology cluster of business, science and education institutions in Vilnius and a competence centre within biotechnology and biopharmaceutical; innovative medicine technologies; molecular medicine and biopharmaceuticals; ecosystems and sustainable development. Santara Valley is one of 5 technology clusters in Lithuania being developed to accelerate translation of research results into business applications.

Share equipment, services, facilities and knowledge with other organizations in the ScanBalt BioRegion. B2B sharing Marketplace for renting out and sell idle capacity, facilities, and staff. On here, we unite supply and demand, and facilitate organizations to generate additional turnover and lower costs through asset sharing. 30 % discounts for members of ScanBalt. The ScanBalt Sharing Marketplace is a product of the collaboration between ScanBalt fmba and FLOOW2 Healthcare, the first Sharing Marketplace for healthcare organizations.

Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious and safe drugs to the market. Selvita Group laboratories have the General Pharmaceutical Inspectorate accreditation and Good Laboratory Practice (GLP) certification. Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Our current projects are in the area of oncology, central nervous system and autoimmune diseases.

Stem Cell Research Centre (SRCR) is a Lithuanian capital company concentrating it's business to applied stem cell research, stem cell banking and regenerative medicine. The Stem Cell Research Centre is also a coordinator of the Lithuanian stem cell and regenerative medicine cluster. This cluster brings together eleven enterprises specializing in stem cell research, clinical research and patient data management, bioengineering and cGMP production.

Syncom provides the pharmaceutical and biotech industries with custom synthesis solutions. As a global leader Syncom can count leading global pharmaceutical companies as well as small virtual startup companies among our clients. In addition to our pharma activities we serve also the diagnostic, fine chemical, electronic and pigment industries.

TBD-Biodiscovery is a centre for manufacturing and development of active pharmaceutical ingredients (both API and HPAPI) and intermediates. Our special expertise covers multistep synthesis of organic compounds and preparation of pheromones, anthracyclines and peptidomimetics. TBD-Biodiscovery has a good track of complicated R&D projects successfully accomplished. Active pharmaceutical ingredients are produced under highest European GMP standards. For several years, we have been providing top class services for biotech, pharma and drug development companies all over the world, including world leaders in pharma industry. We take professional care of your product, starting from route-scouting up to pilot plant scale and ASMF/DMF compilation.

Triade is a network organization which supports researchers and entrepreneurs with the development of products, setting up a proper administration, and finding the right accommodation and funding. In order to achieve this, Triade makes use of its national and international networks with extensive knowledge and experience with regards to health care related innovations. Triade is affiliated with the University Medical Center Groningen (UMCG) and is subdivided in four departments.